Company news

Aprea Therapeutics, Inc. news in 2023

Aprea Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update

November 8, 2023

Aprea Therapeutics Announces Two Posters at the Upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

September 18, 2023

Aprea Announces Preclinical Data Supporting Highly Differentiated WEE1 Inhibitor, ATRN-1051, Relative To Other WEE1 Inhibitors

September 10, 2023

Aprea Therapeutics Appoints Dr. Jean-Pierre Bizzari to its Board of Directors and Names Dr. Richard Peters as Chairman

August 23, 2023

Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operations

August 9, 2023

Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations

May 14, 2023

Aprea Therapeutics Appoints Gabriela Gruia, M.D. to Board of Directors

May 7, 2023

Aprea Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Update on Business Operations

March 29, 2023

Aprea Therapeutics Announces Closing of $5.5 Million Underwritten Public Offering of Common Stock

February 26, 2023

Aprea Therapeutics Announces Proposed Public Offering of Common Stock

February 21, 2023

Aprea Therapeutics Announces Pricing of $5.5 Million Underwritten Public Offering of Common Stock

February 21, 2023

Aprea Therapeutics Announces Phase II SBIR Award from the National Cancer Institute (NCI)

February 14, 2023

Aprea Therapeutics Announces One-for-Twenty Reverse Stock Split

February 12, 2023

Aprea Therapeutics Appoints John Hamill as Chief Financial Officer

January 29, 2023

Aprea Therapeutics Announces Dosing of First Patient in Phase 1/2a Clinical Trial of Oral ATR Inhibitor ATRN-119 for the Treatment of Advanced Solid Tumors

January 10, 2023

Decks in 2023